CA-SITETRACKER
17.12.2020 15:02:09 CET | Business Wire | Press release
Sitetracker, the global standard for managing high-volume telecom projects, announces the milestone of over 500 Sitetracker Certifications in year one. Sitetracker Certification is a five-day online course that culminates with an exam and creates efficient, power users of Sitetracker.
Launched in January, 2020, with in-person classes, the curriculum shifted online, making it easy for Sitetracker users across the globe to become Sitetracker Certified.
Sitetracker Certification is an immersive deep dive into the Sitetracker platform, based on real-world business challenges specific to the critical infrastructure industry. By tackling the problems through a series of hands-on exercises and collaborative round table discussions, participants leave the one-of-a-kind course with the advanced Sitetracker skills and experience needed to maximize the utilization and potential of their Sitetracker orgs.
The online interactive course is one of the best ways to interact with fellow Sitetracker power users in the vast Sitetracker ecosystem. When the course finishes, sharing best practices and insights among peers continues in the Sitetracker Community - a one-stop online shop for all Sitetracker users to connect and continue their Sitetracker education.
“It is great to be Sitetracker Certified,” said April Magliaro, Director of Operations, Process, and Analysis at ZenFi Networks. “Graduating proves that I know how to use the tool that is the industry standard.”
“We are so excited to have crossed the milestone of 500 certifications. It has been amazing to certify our customers and partners around the globe over the past year,” said Lisa McNicholas, Education Analyst at Sitetracker. “Offering Certification courses at different times via Zoom made it possible for us to expand our reach and certify Sitetracker users from Australia to London to rural Scotland and everywhere in between.”
“With employers searching for candidates that are Sitetracker Certified becoming the norm in telecom and critical infrastructure sectors, earning Sitetracker Certification is quickly becoming a must have course on your CV,” said Giuseppe Incitti, CEO at Sitetracker. “It is an honor to be helping build the next generation of critical infrastructure leaders. So, if you’re in the industry and want to stay ahead of the curve, Sitetracker Certification is a great place to start.”
500 Sitetracker Certified users are only the beginning. With additional courses launching this year, Sitetracker is excited to add more of our customers to the ecosystem of certified professionals worldwide. If you want to learn more about Sitetracker Certification, register ASAP. 2021 spots are already filling up !
About Sitetracker
Sitetracker, Inc. powers the successful deployment of critical infrastructure. As the global standard for managing high-volume projects, the Sitetracker Platform enables growth-focused innovators to optimize the entire asset lifecycle. From the field to the C-suite, Sitetracker enables stakeholders to optimize how they plan, deploy, maintain, and grow their capital asset portfolios. Market leaders in the telecommunications, utility, smart cities, and energy industries — such as Vodafone, Ericsson, Black & Veatch, Google Fiber, and Chargepoint — rely on Sitetracker to manage millions of sites and projects representing over $25 billion of portfolio holdings globally. For more information, visit www.sitetracker.com .
View source version on businesswire.com: https://www.businesswire.com/news/home/20201217005296/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 15:00:00 CEST | Press release
Newest expansion of the NetBrain platform delivers Agent Skills, AI Path Doctor, MCP Server, and expanded cross-domain integrations, extending the agentic capabilities already running in production at hundreds of enterprises. NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 14:00:00 CEST | Press release
News summary: Non-practicing entity litigation continues to create costly, time-consuming pressure across the technology industry Adtran has reached a full settlement following counterclaims, with payment made to Adtran and all claims dismissed with prejudice Outcome reflects Adtran’s commitment to defend its innovations, customers and business against meritless patent assertions Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consi
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 12:50:00 CEST | Press release
Transaction advances portfolio transformation, sharpens focus on higher-growth, higher-margin businesses, strengthens balance sheet, and enhances value creation for shareholders IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio tr
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 12:00:00 CEST | Press release
Data represents the longest reported follow-up for a next-generation BTK inhibitor in CLL, showing sustained disease control and benefit that extends beyond first-line therapyBRUKINSA plus next-generation BCL2 inhibitor sonrotoclax (ZS) delivered deep, durable, and rapid uMRD responses, raising the bar for potential time-limited treatments in CLLData reinforce BeOne’s leadership in CLL and the strength of its foundational hematology franchise BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 pati
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom